The medications, at least while they are patented, are likely to be quite expensive and therefore unlikely to be super cost-effective. I have some links in the article that go into estimating cost-effectiveness of GLP-1 agonists, and it doesn’t look too exciting. That being said, if there was a way to make them cheaper by 2-3 orders of magnitude (not sure how feasible), maybe this picture changes.
In addition, I would worry that access to them (as with all medicines) does reduce how scalable an itervention it is.
Yeah, I think that this is probably an area of pharma where the market has sufficient incentives and is vast, and don’t think there is that much scope for and/or benefit of a new organisation, profit or non profit :)
Hey Gavin, good question. My intuition is that:
The medications, at least while they are patented, are likely to be quite expensive and therefore unlikely to be super cost-effective. I have some links in the article that go into estimating cost-effectiveness of GLP-1 agonists, and it doesn’t look too exciting. That being said, if there was a way to make them cheaper by 2-3 orders of magnitude (not sure how feasible), maybe this picture changes.
In addition, I would worry that access to them (as with all medicines) does reduce how scalable an itervention it is.
Yeah, I think that this is probably an area of pharma where the market has sufficient incentives and is vast, and don’t think there is that much scope for and/or benefit of a new organisation, profit or non profit :)